ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden

Παρόμοια τεκμήρια

• Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
  ανά: Yonal-Hindilerden, Ipek, κ.ά.
  Έκδοση: (2015)
• JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
  ανά: Silver, Richard T., κ.ά.
  Έκδοση: (2010)
• The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
  ανά: Deininger, Michael, κ.ά.
  Έκδοση: (2015)
• Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden
  ανά: Tremblay, Douglas, κ.ά.
  Έκδοση: (2020)
• Effect of busulfan on JAK2V617F allele burden
  ανά: Randi, Maria Luigia, κ.ά.
  Έκδοση: (2014)